A Missouri judge approved a $7.25 billion settlement Friday resolving thousands of claims that Bayer’s Roundup weedkiller causes non-Hodgkin lymphoma.
St. Louis Circuit Judge Timothy Boyer called the deal “fair, reasonable, and adequate” and said the total payout ranks “among the largest in the history of mass tort personal-injury class action settlements.” The ruling covers current cancer patients and people who may be diagnosed in the future. Individual awards range from $10,000 to $165,000 depending on product use, diagnosis date and illness severity. The settlement includes $600 million for attorneys’ fees.
Supreme Court Ruling Reshaped the Case
The approval comes five months after the U.S. Supreme Court dealt a blow to plaintiffs. In a 7-2 decision in June, the high court ruled that federal pesticide law bars failure-to-warn claims brought under state law, undercutting a central pillar of the Roundup litigation. The court overturned a $1.25 million jury award for a Missouri man, John Durnell, who blamed years of glyphosate exposure for his cancer.
That precedent shifted bargaining power decisively toward Bayer. Judge Boyer noted in his order that rejecting the settlement risked pushing the company toward bankruptcy protection, which would have left claimants waiting “an indeterminate number of years” for any payment.

Christopher Seeger, a lawyer for many of the plaintiffs, said the Durnell decision “narrowed the ability of Roundup victims to pursue claims in court” but added, “We look forward to getting this relief into the hands of all Roundup victims as quickly as possible.”
How the Payouts Break Down
The settlement establishes a fund that Bayer will feed with annual payments for up to 21 years, providing as much as $7.25 billion. That is on top of the roughly $10 billion the company has already paid to resolve earlier rounds of litigation. Bayer has seen its share price fall 46% since it bought Monsanto for $63 billion in 2018.
Objections Over Adequacy and Future Exposure
Not all plaintiffs’ lawyers supported the agreement. During a September fairness hearing, attorney Gerson Smoger called it “the scariest, worst future settlement that’s ever been contemplated.” He argued it locks in future claimants for decades with no chance at punitive damages while “kept the product that they were exposed to on the market, allowing the victims to continue to be exposed.”
Bayer denies that its Roundup product causes cancer. The company points to determinations by the U.S. Environmental Protection Agency and other regulators that glyphosate is not likely to be carcinogenic when used as directed. That contradicts the World Health Organization’s International Agency for Research on Cancer, which classified the chemical as “probably carcinogenic” in 2015.
What Remains Unresolved
The settlement does not cover some lawsuits that remain pending in federal court. Bayer has said that about 200 of those cases were still being litigated, and that the supreme court decision gave it strong defenses.
In October, a Missouri jury sided with Bayer in a case alleging design defects, negligence and fraud. Bayer’s U.S. general counsel and global litigation leader, Bill Dodero, said that verdict “should send a strong signal” that future plaintiffs “will face significant challenges.”
The decision can still be appealed. For now, the approval marks what Bayer CEO Bill Anderson called “a decisive milestone in the company's strategy to mitigate the risks of both pending and future Roundup litigation” — a strategy that has seen Bayer remove glyphosate from its new versions of Roundup sold for residential markets.
Founded in 1863 in Barmen as a dyestuffs partnership between Friedrich Bayer and Johann Friedrich Weskott, Bayer launched Aspirin in 1899, creating one of the world’s most recognizable medicines.
The company merged into IG Farben in 1925 and was reincorporated after Allied forces seized the conglomerate’s assets following World War II. Its 2016 acquisition of Monsanto for $63 billion, the largest ever by a German company, brought the Roundup litigation that now threatens its financial standing.
Bayer had faced approximately 65,000 claims in U.S. state and federal courts from people who said they developed cancer after using Roundup at home or on the job. The settlement announced in February aimed to resolve nearly all current and future Roundup claims in the United States. Roundup was developed by Monsanto in the 1970s. In one case, a Georgia jury awarded plaintiffs $2.1 billion.